<DOC>
<DOCNO>
EP-0003667
</DOCNO>
<TEXT>
<DATE>
19790822
</DATE>
<IPC-CLASSIFICATIONS>
C07D-457/00 A61P-25/00 <main>C07D-457/02</main> C07D-457/02 A61K-31/48 A61P-5/00 A61P-43/00 C07D-457/04 
</IPC-CLASSIFICATIONS>
<TITLE>
ergoline compounds, their preparation and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
lilly co elius<sep>eli lilly and company<sep>eli lilly and company307, east mccarty streetindianapolis indiana 46285us<sep>eli lilly and company  <sep>
</APPLICANT>
<INVENTOR>
bach nicholas james<sep>kornfeld edmund carl<sep>bach, nicholas james<sep>kornfeld, edmund carl<sep>bach, nicholas james4269, burkhart, east driveindianapolis indiana 46227us<sep>kornfeld, edmund carl5159 e 76th. courtindianapolis indiana 46250us<sep>bach, nicholas james<sep>kornfeld, edmund carl<sep>bach, nicholas james4269, burkhart, east driveindianapolis indiana 46227us<sep>kornfeld, edmund carl5159 e 76th. courtindianapolis indiana 46250us<sep>
</INVENTOR>
<ABSTRACT>
novel ergoline compounds of the following formula  are described:    wherein r¹ is ethyl, n-propyl, or allyl; y is o, s, so, or so₂;  x is hydrogen, chloro, or bromo; the dotted line represents  the optinal presence of a double bond; and the pharmaceutically-acceptable  acid addition salts thereof.  the compounds  are useful to inhibit prolactin secretion or to treat  parkinson's syndrome.  
</ABSTRACT>
</TEXT>
</DOC>
